MyelinWatch EL
← Pipeline
Planned / announced human trialAnnounced / plannedRegulatory development

Phase 2 • planned

Lucid-MS / Lucid-21-302

PAD2 inhibitor • progressive MS

Practical availability: Research record — not presented as established care

Compound / intervention
PAD2 inhibitor • progressive MS
Mechanism
PAD2 inhibition
Development stage
Phase 2 • planned
Status
FDA IND cleared • public trial registration not located
Population / locations
Sites have not been published • not recruiting in Greece
Evidence level
Human development milestone • no MS efficacy data
Next substantive checkpoint

Public Phase 2 registration, sites and recruitment opening

Company filingOpen source ↗Last checked: 16 Sep 2026

Related substantive developments

Planned / announced human trialAnnounced / plannedRegulatory development

Phase 2 • planned

Lucid-MS: FDA lifts the clinical hold, allowing a planned Phase 2 to move forward

After an earlier clinical hold, the FDA allowed the Lucid-MS IND to proceed. The company plans a randomised, double-blind, placebo-controlled Phase 2 in progressive MS for the PAD2 inhibitor Lucid-21-302.

Practical availability: Research record — not presented as established care

What this means clinically

This is permission to begin clinical development, not evidence that the drug remyelinates or improves outcomes. As of 16 September 2026, no public Phase 2 registration or recruiting site had been located.

Source quality: Official company SEC filing • not a peer-reviewed efficacy result

Company filingSEC filing / Quantum BioPharma ↗